ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
February 26, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
The WHO considers infertility a global...
ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
February 23, 2018 16:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
February 07, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
February 01, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018
January 05, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
December 07, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA...
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
December 05, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
OBE022 is a first-in-class, oral and...
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
November 14, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- All Three Development Compounds...
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
November 07, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
October 31, 2017 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...